| scholarly article | Q13442814 |
| P50 | author | Matthew N Hurley | Q57565689 |
| P2093 | author name string | A. Smyth | |
| M. Hurley | |||
| P2860 | cites work | Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis | Q24188313 |
| Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis | Q24201445 | ||
| Inhaled antibiotics for long-term therapy in cystic fibrosis | Q24235635 | ||
| Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis | Q24240388 | ||
| Fluoroquinolone safety in pediatric patients: a prospective, multicenter, comparative cohort study in France | Q28207792 | ||
| A critical review of the fluoroquinolones: focus on respiratory infections | Q28215446 | ||
| Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. | Q30413773 | ||
| Safety profile of the fluoroquinolones: analysis of adverse drug reactions in relation to prescription data using four regional pharmacovigilance databases in Italy | Q33654583 | ||
| Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial | Q33861117 | ||
| Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis | Q33983611 | ||
| Mechanism of action of and resistance to quinolones | Q34408434 | ||
| Antimicrobials: Modes of Action and Mechanisms of Resistance | Q35127138 | ||
| Ciprofloxacin safety in paediatrics: a systematic review | Q35161454 | ||
| Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. | Q36057093 | ||
| Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group | Q38505793 | ||
| Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. | Q39781130 | ||
| Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line | Q40225402 | ||
| Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients | Q40284573 | ||
| Defining a pulmonary exacerbation in cystic fibrosis | Q40685895 | ||
| A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β-lactams in Pseudomonas aeruginosa. | Q42118850 | ||
| Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs | Q42200170 | ||
| Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis | Q42930109 | ||
| Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. | Q43216747 | ||
| Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial | Q43227275 | ||
| Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients | Q43261510 | ||
| Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis | Q43275129 | ||
| Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis | Q43574441 | ||
| Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation | Q43591303 | ||
| Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? | Q43607414 | ||
| Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis | Q43754593 | ||
| Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa | Q43891609 | ||
| Use of ciprofloxacin in cystic fibrosis patients | Q43922470 | ||
| Oral fluoroquinolones and the risk of retinal detachment | Q44055581 | ||
| Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients | Q44067245 | ||
| Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis | Q44248035 | ||
| Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment | Q44420419 | ||
| Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis | Q44603672 | ||
| Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience | Q46436058 | ||
| Assessing the diagnostic importance of nonviable bacterial cells in respiratory infections | Q46436677 | ||
| Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa | Q46745363 | ||
| Fluoroquinolone-induced suicidal ideation and suicidality | Q48765772 | ||
| Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. | Q51449327 | ||
| Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. | Q53139077 | ||
| Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. | Q54131581 | ||
| The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. | Q54399290 | ||
| Detection of Anaerobic Bacteria in High Numbers in Sputum from Patients with Cystic Fibrosis | Q57913654 | ||
| Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin | Q69255054 | ||
| Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis | Q72993581 | ||
| Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis | Q74357144 | ||
| Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis | Q77377382 | ||
| Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa | Q83797983 | ||
| Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study | Q83817190 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cystic fibrosis | Q178194 |
| P304 | page(s) | 363-73 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | Therapeutic advances in respiratory disease | Q26842252 |
| P1476 | title | Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis | |
| P478 | volume | 6 |
Search more.